Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p27
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 27/191)
Character Range: 9753483–9768205

support as part of an assisted reproductive technology (ART) treatment cycle for infertile women; AND
                                                                                                                                                                                                                               Patient must be receiving medical services as described in items 13200 or 13201 of the Medicare Benefits Schedule.
                                                                                                                                                                                                                               The luteal phase is defined as the time span from embryo transfer until implantation confirmed by positive B-hCG measurement.
C5046               P5046          CN5046           Cetrorelix                                                                                                                                                                 Assisted Reproductive Technology                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Compliance with Authority Required procedures - Streamlined Authority Code 5046
                                                                                                                                                                                                                               The treatment must be for prevention of premature luteinisation and ovulation; AND
                                                    Ganirelix                                                                                                                                                                  Patient must be undergoing controlled ovarian stimulation; AND
                                                                                                                                                                                                                               Patient must be receiving medical services as described in items 13200, 13201, 13202 or 13203 of the Medicare Benefits Schedule.
                                                    Nafarelin

                                                    Triptorelin

C5087               P5087          CN5087           Poly-l-lactic acid                                                                                                                                                         Severe facial lipoatrophy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures
                                                                                                                                                                                                                               Initial PBS-subsidised treatment
                                                                                                                                                                                                                               The treatment must be for facial administration only; AND
                                                                                                                                                                                                                               The condition must be caused by therapy for HIV infection.
                                                                                                                                                                                                                               Accreditation following completion of injection administration training with Galderma is required to prescribe poly-l-lactic acid under the PBS. Patients must be referred from the HIV physician to the accredited injector.
C5089               P5089          CN5089           Calcitriol                                                                                                                                                                 Hypophosphataemic rickets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures - Streamlined Authority Code 5089

                                                    Sodium acid phosphate

C5094               P5094          CN5094           Darunavir                                                                                                                                                                  Human immunodeficiency virus (HIV) infection                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Compliance with Authority Required procedures - Streamlined Authority Code 5094
                                                                                                                                                                                                                               The treatment must be in addition to optimised background therapy; AND
                                                                                                                                                                                                                               The treatment must be in combination with other antiretroviral agents; AND
                                                                                                                                                                                                                               The treatment must be co-administered with 100 mg ritonavir twice daily; AND
                                                                                                                                                                                                                               Patient must have experienced virological failure or clinical failure or genotypic resistance after at least one antiretroviral regimen.
                                                                                                                                                                                                                               Virological failure is defined as a viral load greater than 400 copies per mL on two consecutive occasions, while clinical failure is linked to emerging signs and symptoms of progressing HIV infection or treatment-limiting toxicity.
C5095               P5095          CN5095           Sodium acid phosphate                                                                                                                                                      Familial hypophosphataemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Compliance with Authority Required procedures - Streamlined Authority Code 5095

C5098               P5098          CN5098           Apixaban                                                                                                                                                                   Pulmonary embolism                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Compliance with Authority Required procedures - Streamlined Authority Code 5098
                                                                                                                                                                                                                               Initial treatment
                                                    Rivaroxaban                                                                                                                                                                Patient must have confirmed acute symptomatic pulmonary embolism.

C5106               P5106          CN5106           Mesna                                                                                                                                                                      Urothelial toxicity
                                                                                                                                                                                                                               Prophylaxis or reduction of toxicity
                                                                                                                                                                                                                               The treatment must be adjunctive therapy to ifosfamide or high dose cyclophosphamide.
C5114               P5114          CN5114           Calcitriol                                                                                                                                                                 Vitamin D-resistant rickets                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 5114

                                                    Sodium acid phosphate

C5122               P5122          CN5122           Poly-l-lactic acid                                                                                                                                                         Severe facial lipoatrophy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures
                                                                                                                                                                                                                               Maintenance PBS-subsidised treatment
                                                                                                                                                                                                                               The treatment must be for facial administration only; AND
                                                                                                                                                                                                                               The condition must be caused by therapy for HIV infection.
                                                                                                                                                                                                                               Accreditation following completion of injection administration training with Galderma is required to prescribe poly-l-lactic acid under the PBS. Patients must be referred from the HIV